Literature DB >> 22019149

The specific disease burden of neuropathic pain: results of a French nationwide survey.

Nadine Attal1, Michel Lanteri-Minet, Bernard Laurent, Jacques Fermanian, Didier Bouhassira.   

Abstract

We report the first nationwide survey of the impact of neuropathic pain, as opposed to nonneuropathic pain, on quality of life and health care utilization in the French general population. A postal questionnaire was sent to a representative sample of 4554 respondents from an initial nationwide survey of 30,155 subjects with or without chronic pain. It included pain characteristics (Neuropathic Pain Symptom Inventory, DN4), quality of life (Medical Outcomes Short Form 12, SF-12), sleep, anxiety/depressive symptoms (Hospital Anxiety and Depression Scale) and health care utilization. In total, 3899 (85.6%) questionnaires were returned, 3816 (97.9%) could be assessed and 3165 subjects (82.9%) confirmed their pain status. Subjects reporting pain and neuropathic characteristics based on the DN4 displayed a higher degree of impairment of all dimensions relating to quality of life and sleep and had higher anxiety/depression scores than those reporting pain without neuropathic characteristics and those without pain (P<.01). They also made greater use of health care facilities, particularly as concerned neurological treatments and visits to neurologists (21% vs 9%; P<.01). Multivariate analyses showed that the neuropathic characteristics of pain made an independent contribution to quality-of-life impairment (P<.0001 and P=.0005 for the physical and mental scores of the SF-12 respectively). Our study indicates that the disease burden of chronic pain depends on the nature of the pain, independently of its intensity and duration.
Copyright © 2011 International Association for the Study of Pain. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 22019149     DOI: 10.1016/j.pain.2011.09.014

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  97 in total

Review 1.  HIV-associated sensory neuropathy: risk factors and genetics.

Authors:  Peter R Kamerman; Antonia L Wadley; Catherine L Cherry
Journal:  Curr Pain Headache Rep       Date:  2012-06

Review 2.  Epidemiology of neuropathic pain and its impact on quality of life.

Authors:  Blair H Smith; Nicola Torrance
Journal:  Curr Pain Headache Rep       Date:  2012-06

Review 3.  [Transcranial magnetic stimulation and motor cortex stimulation in neuropathic pain].

Authors:  V Mylius; S S Ayache; M Teepker; C Kappus; M Kolodziej; F Rosenow; C Nimsky; W H Oertel; J P Lefaucheur
Journal:  Schmerz       Date:  2012-12       Impact factor: 1.107

Review 4.  Reappraising neuropathic pain in humans--how symptoms help disclose mechanisms.

Authors:  Andrea Truini; Luis Garcia-Larrea; Giorgio Cruccu
Journal:  Nat Rev Neurol       Date:  2013-09-10       Impact factor: 42.937

5.  Photobiomodulation therapy by NIR laser in persistent pain: an analytical study in the rat.

Authors:  Laura Micheli; Lorenzo Di Cesare Mannelli; Elena Lucarini; Francesca Cialdai; Leonardo Vignali; Carla Ghelardini; Monica Monici
Journal:  Lasers Med Sci       Date:  2017-07-28       Impact factor: 3.161

6.  Mapping painDETECT, a neuropathic pain screening tool, to the EuroQol (EQ-5D-3L).

Authors:  Joseph C Cappelleri; Vijaya Koduru; E Jay Bienen; Alesia Sadosky
Journal:  Qual Life Res       Date:  2016-08-02       Impact factor: 4.147

7.  Intrathecal Administration of Tempol Reduces Chronic Constriction Injury-Induced Neuropathic Pain in Rats by Increasing SOD Activity and Inhibiting NGF Expression.

Authors:  Baisong Zhao; Yongying Pan; Zixin Wang; Yonghong Tan; Xingrong Song
Journal:  Cell Mol Neurobiol       Date:  2015-10-03       Impact factor: 5.046

8.  Chronic neuropathic pain negatively associated with employment retention of cancer survivors: evidence from a national French survey.

Authors:  Caroline Alleaume; Marc-Karim Bendiane; Anne-Déborah Bouhnik; Dominique Rey; Sébastien Cortaredona; Valérie Seror; Patrick Peretti-Watel
Journal:  J Cancer Surviv       Date:  2017-10-04       Impact factor: 4.442

9.  Anxiolytic effects of the novel α2δ ligand mirogabalin in a rat model of chronic constriction injury, an experimental model of neuropathic pain.

Authors:  Hiroyasu Murasawa; Hiroyuki Kobayashi; Kensuke Saeki; Yutaka Kitano
Journal:  Psychopharmacology (Berl)       Date:  2019-09-12       Impact factor: 4.530

10.  Neuropathic Pain Among Community-Dwelling Older People: A Clinical Study in Finland.

Authors:  Susanna Rapo-Pylkkö; Maija Haanpää; Helena Liira
Journal:  Drugs Aging       Date:  2015-09       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.